• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Panacea Biotec terminates MoU with Refana for COVID-19 vaccine

expresspharmaAugust 24, 2020

Tag: COVID-19 vaccine , Refana , Panacea Biotec

Panacea Biotec has terminated the MOU for development, manufacture and supply of a vaccine for COVID-19 in collaboration with Refana. The MOU, executed on June 9, 2020, was terminated with effect from August 21, 2020.

The company informed that the termination is due to delays in project timelines and difficulty in moving ahead with the joint venture.

It will not pursue the development of COVID-19 vaccine project in collaboration with Refana and will not make any investment in the joint venture company proposed under the MOU, informed the company through a statement.

Previous:China gives emergency authorisation for COVID-19 vaccines: Official

Next:Granules Pharma receives US FDA approval for Ramelteon tablets

Related News

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

Macrogen and Illumina Inc. (NASDAQ: ILMN) announced today that they are honoured to support the National Bio Big Data project by sequencing and analysing 145,952 Korean genomes.

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Panacea Biotec terminates MoU with Refana for COVID-19 vaccine | Pharmasources.com

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Manulife Hong Kong today announced a new partnership with New Frontier Group, one of the leading healthcare service providers in Greater China, to introduce cashless services for eligible customers through New Frontier Group's subsidiary, Prosper Health.

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins
CEFIXIME cephalosporins

CEFIXIME cephalosporins
CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins
CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins
CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service